top of page
About
Technology
Vaccine Pipeline
News
Contact
More
Use tab to navigate through the menu items.
All Posts
Press Releases
In the News
Search
Jun 14, 2022
The Scientist: Nasal Vaccines Are Commercially High Risk, Perhaps High Reward
Apr 25, 2022
Bloomberg BusinessWeek: Why Nasal Sprays Are Poised to Be the Next Weapon for Fighting Covid
Apr 11, 2022
The Washington Post: The Next Leap in Coronavirus Vaccine Development Could Be a Nasal Spray
Mar 10, 2022
News Channel Nebraska: Hastings Doctor Leading ‘History-Making’ RSV Vaccine Trial
Nov 2, 2021
FierceBiotech: Meissa's Early Clinical Data on COVID-19 Vaccine Supports Transmission Blocking Role
Oct 28, 2021
Yahoo! News: A Nasal COVID-19 Vaccine Could Be the Solution to Ending the Pandemic, Experts Say
Oct 14, 2021
JAMA: Trying to Block SARS-CoV-2 Transmission With Intranasal Vaccines
Jul 26, 2021
BioPharm International: Meissa’s Intranasal COVID-19 Vaccine Yields Promising Preclinical Data
Jul 22, 2021
Science: Scent of a Vaccine
Jul 22, 2021
National Geographic: A Spritz Instead of a Jab? Future COVID-19 Vaccines May Go up Your Nose.
Jul 20, 2021
Reuters: Intranasal Vaccine Aims to Block Virus at Point of Entry
Jul 19, 2021
BioSpace: Meissa's Intranasal COVID-19 Vaccine Shows Promise in Non-Human Primates
Jul 19, 2021
MedCity News: Meissa Vaccines’ Leg up in the Covid-19 Vaccines Chase Goes through the Nose
Jul 18, 2021
Big4Bio Podcast: How a Long Effort to Protect Against RSV May Lead to a Better COVID-19 Vaccine
Jul 11, 2021
Big4Bio: Building Single Dose, Intranasal Vaccines to Prevent COVID-19 and RSV
Jul 4, 2021
Big4Bio: Meissa Vaccines Is Driven to Rid the World of Viral Respiratory Scourges
May 24, 2021
Biotech 2050 Podcast: An End Game Vaccine for COVID-19
Mar 24, 2021
BioSpace: Meissa’s Intranasal COVID-19 Vaccine Uses Codon Deoptimization for Stronger Responses
Jul 30, 2020
San Francisco Business Times: Covid Vaccine Player Hopes to Start Clinical Trial Early Next Year
Jul 20, 2020
BioSpace: Another COVID-19 Vaccine Joins the Race – This Time, it’s a Live, Weakened Virus
Sep 26, 2019
FierceBiotech: Meissa Raises $30M to Take RSV Vaccine into the Clinic
Sep 26, 2019
Xconomy: Meissa Scores $30M to Test Vaccine for Dangerous Respiratory Virus
Sep 26, 2019
Endpoints: Meissa Obtains $30M Series A to Test Synthetic Biology Approach to 'Elusive' RSV Vaccines
bottom of page
